A case of erythrodermic psoriasis successfully treated with guselkumab
- 30 January 2020
- journal article
- research article
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (2) , e13238
Abstract
Erythrodermic psoriasis (EP) is the most severe form of psoriasis, resulting in significant morbidity and mortality. EP treatment with biologics is not well ruled by international guidelines, so most biological drugs are used basing on case reports or small case series. Guselkumab, a fully human anti‐interleukin (IL)‐23 monoclonal antibody, is approved for moderate to severe plaque psoriasis while its use in EP is off label. To date, no case reports on Caucasian patients have been described in literature. We report the case of 38‐year‐old Caucasian male with EP successfully treated with guselkumab, reaching PASI 100 after 20 weeks of therapy and still maintaining this response at week 48. Our case report suggests guselkumab as an efficacious and well tolerated treatment in EP, presenting a long term efficacy in the prevention of recurrences. Further studies are warrant to confirm our data, with controlled trials specifically dedicated to EP being strictly needed in order to verify the role and efficacy of anti‐IL23 in EP.Keywords
This publication has 7 references indexed in Scilit:
- Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label studyThe Journal of Dermatology, 2018
- Guselkumab for the treatment of psoriasisExpert Opinion on Biological Therapy, 2018
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trialJournal of the American Academy of Dermatology, 2017
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trialJournal of the American Academy of Dermatology, 2017
- The role of histological presentation in erythrodermaInternational Journal of Dermatology, 2017
- Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic DermatitisJAMA Dermatology, 2015
- Specific targeting of interleukin-23p19 as effective treatment for psoriasisJournal of the American Academy of Dermatology, 2014